Amarantus Bioscience Holdings Inc (AMBS)

[Ann1]

If you recall, the AMBS CEO said that on the business model side, AMBS was going to generate revenue in 2013. Um, that's THIS YEAR! And that was going to happen through diagnostics. See below article out TODAY.

http://seekingalpha.com/article/1101761-first-half-of-2013-to-be-a-critical-time-for-exact-sciences?source=yahoo

"In other M&A news in the space, Amarantus BioScience (AMBS.OB), a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis, announced the company purchased all of the intellectual property assets from Power3 Medical Products.

As part of the transaction, Amarantus took ownership of 20 pending patent applications covering a variety of biomarkers and assays related to the treatment of various diseases including Parkinson's, Alzheimer's, and ALS, as well as patent applications related to Breast Cancer, neuromuscular disease and Chronic Myelogenous Leukemia. The company also acquired all of the data generated by Power3 while creating its IP portfolio. All of the disease states covered by the intellectual property acquired from Power3 are related to Programmed Cell Death (Apoptosis)."